In men who are overweight or have type 2 diabetes, yes - a wave of 2025 research has linked GLP-1 drugs such as semaglutide and tirzepatide (the medicines sold as Ozempic, Wegovy, Mounjaro and Zepbound) to real increases in testosterone, with more men moving into the normal range as they lose weight. But the effect appears to be driven by the weight loss itself, it shows up mainly in men whose low testosterone is tied to excess weight, and it is not seen in healthy men. That nuance is the whole story, and it is where most of the headlines go wrong.
This is one of the most searched men's-health questions of the year, and for good reason: millions of men are now taking GLP-1 medications for weight or blood sugar, and many of them also have low testosterone. When a drug that is already in your medicine cabinet might also lift your testosterone, the appeal is obvious. The question deserves an honest answer rather than a hyped one.
The honest answer has two halves. The encouraging half: multiple studies presented in 2025, plus several systematic reviews, consistently found higher total testosterone in men with obesity or type 2 diabetes who took GLP-1 drugs - in some cases enough to move a majority of men from low into the normal range. The cautious half: the evidence is early, much of it was presented at conferences rather than fully peer-reviewed, the studies are mostly small and short, the gains track almost perfectly with weight loss, and the drugs did nothing for testosterone in men who were already lean and healthy.
This guide walks through all of it - what the studies actually found, why weight loss is the likely mechanism, who benefits, who doesn't, and how GLP-1s and testosterone replacement fit together. For the bigger picture of low testosterone and its treatment, start with our complete guide to TRT and our guide to what causes low testosterone, where excess weight features heavily.
